We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being de... Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. Show more
Ask ADVFN Intelligence (AI)
- Veligrotug, with recent positive phase 3 topline data in both active and chronic thyroid eye disease (TED), has the potential to transform the standard of care in TED with a differentiated...
- Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p <...
- THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.17 | 6.40744797371 | 18.26 | 19.79 | 17.96 | 823317 | 18.76983249 | CS |
| 4 | -0.05 | -0.256673511294 | 19.48 | 21.58 | 16.6 | 1297074 | 18.80896448 | CS |
| 12 | -5.03 | -20.5641864268 | 24.46 | 27.2 | 16.6 | 1452402 | 20.17856102 | CS |
| 26 | 1.52 | 8.48687883864 | 17.91 | 27.2 | 13.2 | 1397798 | 19.83332414 | CS |
| 52 | -0.7 | -3.47739692002 | 20.13 | 27.2 | 11.4 | 1175298 | 18.08752267 | CS |
| 156 | 1 | 5.42593597396 | 18.43 | 39 | 9.47 | 794507 | 19.84266021 | CS |
| 260 | -1.96 | -9.16316035531 | 21.39 | 39 | 9.47 | 615136 | 19.6772594 | CS |
Monksdream
5 months ago
it_happens
5 months ago
power11
5 months ago
it_happens
5 months ago
power11
5 months ago
it_happens
5 months ago
Monksdream
5 months ago
Apprentice
3 years ago
Apprentice
3 years ago
crudeoil24
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
